{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T10:34:47Z","timestamp":1781865287859,"version":"3.54.5"},"reference-count":30,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2005,5,23]],"date-time":"2005-05-23T00:00:00Z","timestamp":1116806400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Endocrinology"],"published-print":{"date-parts":[[2005,7]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p><jats:bold>Objective\u2002<\/jats:bold> Reports suggest that up to 70% of patients with microprolactinomas treated with dopamine agonist therapy may achieve long\u2010term normoprolactinaemic remission following drug withdrawal. Yet, there is no consensus on the duration of therapy nor is therapeutic interruption universally practised. We have assessed remission rates in a large cohort of treatment\u2010naive subjects with microprolactinomas. Subjects received dopamine agonist (DA) therapy with either cabergoline or bromocriptine for a period of 2 to 3\u00a0years in the majority of cases, followed by a trial of treatment withdrawal.<\/jats:p><jats:p><jats:bold>Design\u2002<\/jats:bold> Retrospective analysis of clinic records of 89 patients (mean age 32\u00b77\u00a0\u00b1\u00a08\u00b74\u00a0years, 84 women and 5 men) who had received either cabergoline (<jats:italic>n<\/jats:italic>\u00a0=\u00a067) (0\u00b75\u20133\u00a0mg weekly) or bromocriptine (<jats:italic>n<\/jats:italic>\u00a0=\u00a022) (2\u00b75\u201310\u00a0mg daily) for a mean duration of 3\u00b71\u00a0years.<\/jats:p><jats:p><jats:bold>Results\u2002<\/jats:bold> Following withdrawal of therapy, 57 subjects developed recurrence (64%) and the mean time to recurrence was 9\u00b76\u00a0months (range 1\u201344\u00a0months), while 32 subjects (36%) remained in remission beyond 1\u00a0year (mean 3\u00b76\u00a0years, range 1\u20137\u00a0years). There was no difference in remission rates between subjects treated with cabergoline (<jats:italic>n<\/jats:italic>\u00a0=\u00a021) and bromocriptine (<jats:italic>n<\/jats:italic>\u00a0=\u00a011), but a direct relationship between pretreatment prolactin concentration and risk of recurrent symptomatic hyperprolactinaemia was observed. No subjects developed clinical features to suggest tumour expansion following therapeutic discontinuation.<\/jats:p><jats:p><jats:bold>Conclusions\u2002<\/jats:bold> This study confirms that abrupt withdrawal of chronic dopamine agonist therapy, following 2 to 3\u00a0years of treatment is safe and associated with long\u2010term remission in 30\u201340% of subjects with microprolactinomas. This therapeutic strategy is convenient and applicable in clinical practice.<\/jats:p>","DOI":"10.1111\/j.1365-2265.2005.02293.x","type":"journal-article","created":{"date-parts":[[2005,6,20]],"date-time":"2005-06-20T12:33:35Z","timestamp":1119270815000},"page":"26-31","source":"Crossref","is-referenced-by-count":90,"title":["Long\u2010term remission following withdrawal of dopamine agonist therapy in subjects with microprolactinomas"],"prefix":"10.1111","volume":"63","author":[{"given":"M.","family":"Biswas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Jadon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"McEwan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D. A.","family":"Rees","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L. M.","family":"Evans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. F.","family":"Scanlon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. S.","family":"Davies","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2005,5,23]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0889-8529(05)70203-6"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1210\/jcem-58-2-268"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1210\/jcem-59-3-463"},{"key":"e_1_2_6_5_2","first-page":"489","article-title":"Cabergoline in the long\u2010term therapy of hyperprolactinaemic disorders","volume":"126","author":"Ferrari C.","year":"1992","journal-title":"Acta Endocrinologica"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.40.857"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa022657"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199410063311403"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1012905415868"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.87.8.3578"},{"key":"e_1_2_6_11_2","first-page":"628","article-title":"Pituitary tumours: recommendations for service provision and guidelines for management of patients","volume":"31","author":"Clayton R.N.","year":"1997","journal-title":"Journal of the Royal College of Physicians"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2265.2003.01678.x"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1053\/beem.1999.0030"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.1981.tb00608.x"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.1983.tb03191.x"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.1991.tb00288.x"},{"key":"e_1_2_6_17_2","first-page":"139","article-title":"Follow\u2010up of patients with prolactinomas after discontinuation of long\u2010term therapy with bromocriptine","volume":"104","author":"Zarate A.","year":"1983","journal-title":"Acta Endocrinologica"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(84)90480-X"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1210\/jcem-60-4-764"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0015-0282(16)59462-X"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.1987.tb01163.x"},{"key":"e_1_2_6_22_2","first-page":"817","volume-title":"Prolactin: Basic and Clinical Correlates","author":"Winkelmann W.","year":"1985"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.1991.tb00289.x"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.1210\/jcem-55-6-1178"},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.1210\/jcem-58-6-1179"},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1445-5994.1985.tb04009.x"},{"key":"e_1_2_6_27_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.1991.tb00299.x"},{"key":"e_1_2_6_28_2","doi-asserted-by":"publisher","DOI":"10.1677\/erc.0.0080287"},{"key":"e_1_2_6_29_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2265.1996.00824.x"},{"key":"e_1_2_6_30_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF03348016"},{"key":"e_1_2_6_31_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.2005.02293.x"}],"container-title":["Clinical Endocrinology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2265.2005.02293.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2265.2005.02293.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,13]],"date-time":"2023-10-13T18:34:39Z","timestamp":1697222079000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2265.2005.02293.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,5,23]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2005,7]]}},"alternative-id":["10.1111\/j.1365-2265.2005.02293.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2265.2005.02293.x","archive":["Portico"],"relation":{},"ISSN":["0300-0664","1365-2265"],"issn-type":[{"value":"0300-0664","type":"print"},{"value":"1365-2265","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,5,23]]}}}